1108 documents

Read All
20:31 , Sep 14, 2018 |  BC Week In Review  |  Company News

Acorda loses Amprya appeal, reports Inbrija PDUFA delay

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $10.30 (37%) to $17.25 the week of Sept. 10 following setbacks related to multiple sclerosis drug Ampyra dalfampridine and Parkinson's disease candidate Inbrija levodopa inhalation powder (CVT-301). On Sept. 10,...
Read More
17:28 , Sep 14, 2018 |  BC Week In Review  |  Company News

ICER finds opioid use disorder treatments not cost-effective

In a draft evidence report, ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value of three...
Read More
23:10 , Sep 10, 2018 |  BC Extra  |  Company News

ICER finds opioid use disorder treatments are not cost-effective

In a draft evidence report, ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value of three...
Read More
20:29 , Sep 10, 2018 |  BC Extra  |  Company News

Acorda loses appeal to shield Ampyra from generic entry

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $6.75 (25%) to $20.80 Monday after the U.S. Court of Appeals for the Federal Circuit upheld a 2017 district court ruling that leaves multiple sclerosis drug Ampyra dalfampridine with no...
Read More
17:44 , Sep 7, 2018 |  BC Week In Review  |  Company News

Alkermes in pay-for-performance deal

Alkermes plc (NASDAQ:ALKS) signed a contract with UPMC Health Plan for opioid antagonist Vivitrol naltrexone that links reimbursement of the drug to positive clinical outcomes when treating opioid dependence. Alkermes spokesperson Matthew Henson did not disclose...
Read More
18:07 , Aug 31, 2018 |  BC Week In Review  |  Company News

Alkermes, Oklahoma negotiating value-based Medicaid purchasing agreements

The Oklahoma Health Care Authority (OHCA) said it has signed its first contract to negotiate value-based Medicaid purchasing agreements with Alkermes plc (NASDAQ:ALKS) for schizophrenia drug Aristada aripiprazole lauroxil. OHCA is also close to agreements for...
Read More
15:12 , Aug 31, 2018 |  BC Extra  |  Company News

Alkermes in pay-for-performance deal

Alkermes plc (NASDAQ:ALKS) signed a contract with UPMC Health Plan for opioid antagonist Vivitrol naltrexone that links reimbursement of the drug to positive clinical outcomes when treating opioid dependence. Alkermes spokesperson Matthew Henson did not disclose...
Read More
21:59 , Aug 24, 2018 |  BC Extra  |  Company News

Alkermes, Oklahoma negotiating value-based Medicaid purchasing agreements

The Oklahoma Health Care Authority (OHCA) said it has signed its first contract to negotiate value-based Medicaid purchasing agreements with Alkermes plc (NASDAQ:ALKS) for schizophrenia drug Aristada aripiprazole lauroxil. OHCA is also close to agreements for...
Read More
06:20 , Aug 10, 2018 |  BC Week In Review  |  Company News

Acorda, Mylan reach settlement for Ampyra generic

Acorda Therapeutics Inc. (NASDAQ:ACOR) reached a conditional settlement with Mylan N.V. (NASDAQ:MYL) that would allow Mylan to market a generic version of multiple sclerosis drug Ampyra dalfampridine in the U.S. in 2025 or earlier under...
Read More
23:03 , Aug 6, 2018 |  BC Extra  |  Company News

Acorda, Mylan reach settlement for Ampyra generic

Acorda Therapeutics Inc. (NASDAQ:ACOR) reached a conditional settlement with Mylan N.V. (NASDAQ:MYL) that would allow Mylan to market a generic version of multiple sclerosis drug Ampyra dalfampridine in the U.S. in 2025 or earlier under...
Read More